TROPION-Breast 03: A Clinical Trial for Patients with Triple-Negative Breast Cancer

The TROPION-Breast 03 clinical trial offers a promising avenue for patients diagnosed with invasive Triple-Negative Breast Cancer (TNBC) who meet specific criteria and are seeking alternative, advanced treatment options. This trial, conducted by Massive Bio, aims to explore innovative therapies to enhance treatment outcomes for those with limited responses to conventional methods.

Who is Eligible for the TROPION-Breast 03 Clinical Trial?

To participate in the TROPION-Breast 03 trial, patients must meet specific inclusion and exclusion criteria. Key eligibility requirements include:

- Diagnosis: Patients must have invasive Triple-Negative Breast Cancer with residual invasive disease in the breast or axillary lymph nodes after completing neoadjuvant therapy.
- No BRCA Mutations: Patients should not have germline BRCA 1/2 mutations.
- Completion of Therapy: Eligible participants must have completed at least six cycles of neoadjuvant therapy that included anthracyclines and/or taxanes.
- No Relapse: There should be no evidence of locoregional or distant relapse post-treatment.
- ECOG Status: Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, indicating full functionality or minor restrictions in daily activities.

Exclusions to Note

Several factors may prevent eligibility for the trial, including:

- Metastatic TNBC: Patients with stage IV TNBC are not eligible.
- Prior Invasive Breast Cancer: A history of invasive breast cancer or recurrent disease post-treatment and surgery disqualifies a patient from participating.
- Previous Treatments: Patients who have received certain therapies, such as PD1/PDL1 inhibitors (other than pembrolizumab) or antibody-drug conjugates (ADCs) targeting topoisomerase I or TROP-2, are excluded.
- Concurrent Treatments: Those undergoing active anti-cancer treatment, systemic hormone replacement therapy, or with active infections (e.g., hepatitis B, C, HIV, or tuberculosis) are also ineligible.

Why Consider the TROPION-Breast 03 Trial?

The TROPION-Breast 03 trial is an opportunity for patients to access cutting-edge research in the fight against TNBC. With support from a dedicated team of specialists and Massive Bio’s extensive clinical network, participants gain access to promising therapies that may provide better outcomes and improved quality of life.

How to Express Interest and Participate

If you are a patient diagnosed with Triple-Negative Breast Cancer (TNBC) and are interested in the TROPION-Breast 03 clinical trial, you can fill out an interest form to receive more information and determine if you meet the participation criteria. Visit Massive Bio's interest form to get started.